II. Indications

  1. BMI >30 or
  2. BMI >27 and one comorbid condition

III. Dosing

  1. Phentermine/Topiramate
    1. Start: 3.75 mg/23 mg for the first 2 weeks
    2. Titrate to maximum of 15 mg/92 mg
  2. Discontinuation
    1. Discontinue if 5% weight loss not achieved at maximum dose at 12 weeks
    2. Taper off gradually (risk of Seizure)

IV. Efficacy

  1. Weight loss is promising at 24 pounds in one year or 10% of body weight
  2. Weight loss of at least 5% in up to 70% of patients at one year

V. Adverse effects

  1. Teratogenic (Topiramate)
    1. Precautions to avoid pregnancy (reliable Contraception) while on Qsymia are paramount
    2. REMS training program (Risk Management) has been developed
    3. Pregnancy Test when initiating medication and then monthly
  2. Tachycardia, Hypertension and Insomnia (Phentermine)
  3. Impaired memory or concentration (Topiramate)
  4. Dizziness
  5. Paresthesias in distal extremities
  6. Altered Taste Sensation

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

qsymia (on 12/21/2016 at Medicaid.Gov Survey of pharmacy drug pricing)
QSYMIA 11.25 MG-69 MG CAPSULE $6.38 each
QSYMIA 15 MG-92 MG CAPSULE $6.40 each
QSYMIA 3.75 MG-23 MG CAPSULE $5.78 each
QSYMIA 7.5 MG-46 MG CAPSULE $5.96 each

Ontology: Phentermine / topiramate (C3475162)

Concepts Pharmacologic Substance (T121)
English Phentermine / topiramate, phentermine-topiramate, PHENTERMINE/TOPIRAMATE

Ontology: Qsymia (C3497630)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C576188
English Qsymia

Ontology: Qnexa (C3530195)

Concepts Pharmacologic Substance (T121) , Carbohydrate (T118)
MSH C577572
English Qnexa